DE602004025119D1 - Neue derivate von 4,4'-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen - Google Patents

Neue derivate von 4,4'-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen

Info

Publication number
DE602004025119D1
DE602004025119D1 DE602004025119T DE602004025119T DE602004025119D1 DE 602004025119 D1 DE602004025119 D1 DE 602004025119D1 DE 602004025119 T DE602004025119 T DE 602004025119T DE 602004025119 T DE602004025119 T DE 602004025119T DE 602004025119 D1 DE602004025119 D1 DE 602004025119D1
Authority
DE
Germany
Prior art keywords
dithiobis
aminobutan
sulphonate
compositions containing
new derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004025119T
Other languages
English (en)
Inventor
Bernard Pierre Roques
Nicolas Inguimbert
Marie-Claude Fournie-Zaluski
Pierre Corvol
Catherine Llorens-Cortes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris 5 Rene Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE602004025119D1 publication Critical patent/DE602004025119D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004025119T 2003-08-06 2004-08-06 Neue derivate von 4,4'-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen Active DE602004025119D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0309700A FR2858617A1 (fr) 2003-08-06 2003-08-06 Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
PCT/FR2004/002106 WO2005014535A1 (fr) 2003-08-06 2004-08-06 Derives de 4,4’-dithiobis-(3-aminobutane-1-sulfonates) nouveaux et compositions les contenant

Publications (1)

Publication Number Publication Date
DE602004025119D1 true DE602004025119D1 (de) 2010-03-04

Family

ID=34073059

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025119T Active DE602004025119D1 (de) 2003-08-06 2004-08-06 Neue derivate von 4,4'-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen

Country Status (14)

Country Link
US (1) US7582797B2 (de)
EP (1) EP1651596B1 (de)
JP (1) JP4718461B2 (de)
AT (1) ATE455097T1 (de)
CA (1) CA2533432C (de)
CY (1) CY1109950T1 (de)
DE (1) DE602004025119D1 (de)
DK (1) DK1651596T3 (de)
ES (1) ES2339354T3 (de)
FR (1) FR2858617A1 (de)
PL (1) PL1651596T3 (de)
PT (1) PT1651596E (de)
SI (1) SI1651596T1 (de)
WO (1) WO2005014535A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931151A1 (fr) * 2008-05-13 2009-11-20 Pharmaleads Soc Par Actions Si Nouveaux derives d'amino-acides, leur procede de preparation et leur utilisation therapeutique
JP5650642B2 (ja) * 2008-08-01 2015-01-07 バイオキシネス ファーマシューティカルズ， インコーポレイテッド メチオニンアナログおよびそれらを使用する方法
EP2439192A1 (de) * 2010-10-07 2012-04-11 Quantum Genomics Verfahren zur Herstellung von (3S,3S') 4,4'-disulfandiylbis (3-aminobutan 1-sulfonsäure)
MX345469B (es) * 2011-12-21 2017-02-01 Quantum Genomics Combinacion de (3s,3s') 4,4'-disulfandiilbis(acido 3-aminobutan 1-sulfonico) y un segundo agente antihipertensivo.
EP2722327A1 (de) * 2012-10-22 2014-04-23 Quantum Genomics Kristalline Phase von (3S,3S') 4,4'-disulfandiylbis (3-Aminobutan 1-Sulfonsäure) mit L-Lysin
JP2017532348A (ja) * 2014-10-17 2017-11-02 ユニバーシティ オブ フロリダ リサーチ ファウンデーション 新規な小分子抗癌剤
TW202100146A (zh) * 2019-03-11 2021-01-01 法商量子基因科技有限公司 用於治療高血壓或心衰竭的化合物及包含其之組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods

Also Published As

Publication number Publication date
FR2858617A1 (fr) 2005-02-11
CY1109950T1 (el) 2014-09-10
EP1651596A1 (de) 2006-05-03
DK1651596T3 (da) 2010-05-10
PT1651596E (pt) 2010-04-16
US7582797B2 (en) 2009-09-01
ATE455097T1 (de) 2010-01-15
CA2533432A1 (fr) 2005-02-17
PL1651596T3 (pl) 2010-08-31
SI1651596T1 (sl) 2010-06-30
CA2533432C (fr) 2013-05-21
US20060205695A1 (en) 2006-09-14
ES2339354T3 (es) 2010-05-19
JP4718461B2 (ja) 2011-07-06
EP1651596B1 (de) 2010-01-13
JP2007501204A (ja) 2007-01-25
WO2005014535A1 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE385419T1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
DK2014304T3 (da) Kolonrensende sammensætninger
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
ATE433447T1 (de) Pyrimiidinverbindungen
SE0303180D0 (sv) Novel compounds
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
SE0302232D0 (sv) Novel Compounds
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200600975A1 (ru) Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
BR0105563A (pt) Derivados e análogos de galantamina
DE60215368D1 (de) Pyranderivate als inhibitoren von ace und nep
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
ATE517626T1 (de) Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition